Lawrence K. Kvols

Lawrence K. Kvols's AcademicInfluence.com Rankings

Lawrence K. Kvols

Medical

#2941

World Rank

#3387

Historical Rank

Oncology

#200

World Rank

#206

Historical Rank

medical Degrees

Lawrence K. Kvols

Philosophy

#8486

World Rank

#11876

Historical Rank

Logic

#5515

World Rank

#6920

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Lawrence K. Kvols Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence K. Kvols's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. (1986) (835)
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms (1991) (815)
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas (2011) (666)
Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial (2010) (647)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. (2004) (561)
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. (1993) (538)
Hepatic resection for metastatic neuroendocrine carcinomas. (1995) (456)
Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. (1990) (390)
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. (2005) (376)
Cytoreductive hepatic surgery for neuroendocrine tumors. (1990) (358)
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. (1981) (324)
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. (2002) (319)
Peptide Receptor Radionuclide Therapy (2004) (317)
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. (2005) (294)
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. (2010) (294)
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. (2005) (291)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. (2006) (289)
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. (2009) (275)
The glucagonoma syndrome. Clinical and pathologic features in 21 patients. (1996) (267)
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma (2007) (256)
Distribution of somatostatin receptors in normal and tumor tissue. (1990) (226)
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. (1982) (219)
Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. (2011) (219)
86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion (2003) (216)
Improved Outcome With Cytoreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors (2006) (212)
External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer (1988) (197)
Outcome of cardiac surgery for carcinoid heart disease. (1995) (187)
Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. (1993) (182)
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. (2012) (175)
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. (1993) (167)
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. (2005) (161)
Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. (1989) (159)
Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). (1987) (157)
Rapid reversal of carcinoid crisis with a somatostatin analogue. (1985) (154)
Multifocal inflammatory leukoencephalopathy with 5‐fluorouracil and levamisole (1992) (151)
Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut (2009) (150)
Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors: An Analysis of the AJCC and ENETS Staging Classifications (2012) (146)
Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. (2006) (144)
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. (2013) (141)
Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors (2011) (139)
Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. (2009) (131)
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience (2014) (122)
Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/Carcinoma (2007) (117)
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. (2005) (114)
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group (2006) (108)
Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. (1979) (108)
Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. (1987) (104)
GEPNETs update: Radionuclide therapy in neuroendocrine tumors. (2014) (104)
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. (2010) (103)
In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. (1992) (103)
In vitro detection of somatostatin receptors in human tumors. (1992) (103)
A Phase II study of high‐dose paclitaxel in patients with advanced neuroendocrine tumors (2001) (102)
Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. (1987) (100)
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. (1995) (94)
A phase I clinical trial of recombinant human tumor necrosis factor (1988) (93)
Treatment of the Malignant Carcinoid Syndrome (1987) (92)
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. (1977) (91)
Metastatic carcinoid tumors and the malignant carcinoid syndrome. (1993) (90)
Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. (1995) (88)
Testicular neoplasms: 29 tumors studied by high-resolution US. (1985) (87)
Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors (2011) (86)
Somatostatin receptors in malignant tissues (1990) (84)
Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia (1994) (82)
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model (2006) (81)
Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors (1997) (81)
Metastatic cancer to the testes: a report of 20 cases and review of the literature. (1989) (79)
Rothmund‐Thomson syndrome in siblings: evidence for acquired in vivo mosaicism (1996) (78)
Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. (2008) (78)
A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. (2011) (76)
OctreoTherTM: Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy (2000) (75)
Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. (1986) (73)
Expression of somatostatin receptors in childhood neuroblastoma. (1994) (72)
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. (1993) (69)
A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. (1994) (67)
Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. (2005) (66)
Synchronous and metachronous bilateral testicular tumors mayo clinic experience (1990) (62)
Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. (1990) (62)
Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine Carcinomas (2009) (62)
Somatostatin receptors in human renal cell carcinomas. (1992) (61)
The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. (1992) (61)
Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. (2006) (59)
In vitro detection of somatostatin receptors in human tumors. (1992) (59)
A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome (1991) (58)
Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors (2007) (58)
In vitro and in vivo detection of somatostatin receptors in human malignant tissues. (1991) (58)
Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. (2007) (57)
Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. (1996) (56)
Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? (2008) (56)
Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. (2014) (55)
Chemotherapy of endocrine malignancies: a review. (1987) (55)
Therapy of the malignant carcinoid syndrome. (1989) (53)
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. (2004) (53)
Chemotherapy of metastatic carcinoid and islet cell tumors. A review. (1987) (53)
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. (1978) (50)
Carcinoid disease of the heart. Surgical management of ten patients. (1992) (49)
Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. (2006) (48)
Metastatic Carcinoid Tumors and the Malignant Carcinoid Syndrome (1994) (47)
Intraoperative and external beam irradiation with or without resection: Mayo pilot experience. (1984) (44)
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. (2012) (42)
Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. (2012) (39)
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma (1988) (38)
Therapeutic considerations for the malignant carcinoid syndrome. (1989) (37)
The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. (2006) (35)
A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours (2007) (34)
The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. (2010) (34)
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial (2015) (34)
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. (2013) (34)
Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. (1993) (34)
Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. (2010) (34)
Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study (2012) (33)
Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. (1997) (33)
Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. (2008) (33)
High-resolution ultrasonographic and pathologic abnormalities of germ cell tumors in patients with clinically normal testes. (1983) (32)
Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. (1994) (31)
Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. (1979) (31)
A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate (1990) (31)
Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. (2009) (30)
Randomized trial of thoracic irradiation plus combination chemotherapy for unresectable adenocarcinoma and large cell carcinoma of the lung. (1979) (27)
Primary signet ring cell adenocarcinoma of the bladder. (1989) (27)
First-Line Treatment of Metastatic Pancreatic Endocrine Carcinomas With Capecitabine and Temozolomide (2008) (26)
Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. (2006) (26)
Transtracheal selective bronchial brushing for pulmonary infiltrates in patients with cancer. (1976) (26)
Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy (2007) (25)
MRI of Pancreatic Islet Cell Carcinoma (1993) (25)
Multimodality Management of “Borderline Resectable” Pancreatic Neuroendocrine Tumors (2017) (24)
Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. (1997) (24)
RUNX1T1: A Novel Predictor of Liver Metastasis in Primary Pancreatic Endocrine Neoplasms (2010) (23)
Familial testicular cancer: report of six cases and review of the literature. (1990) (23)
Phase I trial of parenteral 6-thioguanine given on 5 consecutive days. (1986) (21)
A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer. (1985) (21)
Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series (2013) (20)
Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors. (2002) (20)
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide (2008) (20)
213 Bi-[ DOTA 0 , Tyr 3 ] Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical AnimalModel (2006) (19)
Residual, recurrent, or unresectable gastrointestinal cancer. Role of radiation in single or combined modality treatment (1985) (19)
Occult primary. (2008) (18)
A phase II study of recombinant human alpha‐interferon in advanced hormone‐refractory prostate cancer (1992) (18)
Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. (1986) (18)
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. (1981) (16)
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma. (1978) (15)
Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2005) (15)
Local control and survival in locally advanced gastrointestinal cancer. (1986) (15)
Phase II evaluation of AMSA in patients with metastatic lung cancer. (1980) (15)
Revisiting C.G. Moertel's land of small tumors. (2008) (15)
Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. (2007) (15)
Phase I–II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma (1991) (15)
Phase II evaluation of PALA in patients with metastatic lung cancer. (1981) (14)
A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancer. (1980) (14)
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. (1986) (14)
Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma (2008) (14)
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy (1990) (14)
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? (1997) (14)
Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure (1985) (14)
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors (2012) (13)
Clinical Trial of Cisplatin and Intensive Course 5‐Fluorouracil for the Treatment of Advanced Colorectal Cancer (1986) (13)
Medical oncology considerations in patients with metastatic neuroendocrine carcinomas. (1994) (13)
Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? (1994) (13)
Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study (2001) (12)
Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer. (1979) (12)
Evaluation of a fixed alternating treatment in patients with advanced breast cancer. (1978) (12)
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma. (1984) (12)
in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (2006) (12)
Effect of the somatostatin analogue octreotide acetate on hemostasis in humans. (1991) (11)
The carcinoid syndrome: a treatable malignant disease. (1988) (11)
External beam vs. intraoperative and external beam irradiation for locally advanced pancreatic cancer (1986) (11)
Indications for and results of intraoperative irradiation for locally advanced colorectal cancer. (1991) (11)
Gastroenteropancreatic neuroendocrine tumours contain a common set of synaptic vesicle proteins and amino acid neurotransmitters. (1993) (10)
Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer. (1987) (10)
Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatic receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumours. (1998) (10)
Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study. (2000) (10)
Dosimetry and biodistribution of an iodine-123-labeled somatostatin analog in patients with neuroendocrine tumors. (1992) (10)
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. (2008) (10)
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. (2012) (10)
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. (2011) (10)
Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. (1984) (9)
Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. (1978) (9)
Phase I study of recombinant leukocyte a interferon (IFN‐α2A, roferon‐A) with doxorubicin in advanced malignant disease (1989) (9)
Phase I Study of Difluoromethylornithine in Combination with Recombinant α2a-Interferon (1988) (9)
Advances in the use of somatostatins in the management of endocrine tumors. (1996) (9)
Cytoplasmic Clusterin Expression Correlates With Pancreatic Neuroendocrine Tumor Size and Pathological Stage (2013) (9)
Molecular and cell biological aspects of gastroenteropancreatic neuroendocrine tumor disease (1994) (9)
Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy. (2000) (8)
Factor IX deficiency and bleeding in a patient with Sheehan's syndrome. (1972) (8)
The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery (1974) (8)
Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas. (1984) (8)
Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. (1987) (8)
CARClNOlD SYNDROME SECONDARY TO A PRIMARY TUMOUR IN A MECKEL'S DIVERTICULUM (1993) (8)
Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors (2003) (8)
An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. (1981) (7)
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung. (1980) (7)
Stage I nonfunctioning neuroendocrine tumors of the pancreas: Surgery or surveillance? (2011) (7)
Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. (1989) (7)
Rebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201-995) in malignant gastrinoma. (1987) (7)
Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer. (1981) (6)
Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. (1977) (6)
Metabolic effects of amino acids (AA) solutions infused for renal radioprotection. (2000) (6)
Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon. (1988) (6)
Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer. (1981) (6)
Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. (2002) (6)
Nuclear medicine imaging of breast cancer. (1996) (6)
External beam irradiation of myocardial carcinoid metastases: a case report (2007) (6)
Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma. (1981) (6)
Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))? (2000) (6)
A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors. (2012) (6)
Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer. (1981) (5)
Elevated neuropeptide levels decrease during liver transplant. (1993) (5)
Radionuclide therapy in neuroendocrine tumors (2014) (5)
Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR (2010) (5)
Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity. (2002) (5)
Neoplasms of the Diffuse Endocrine System (2003) (5)
Carcinoid syndrome secondary to a primary tumour in a Meckel's diverticulum. (1993) (5)
Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (2010) (5)
Amino acid (AA) solutions infused for renal radioprotection: Metabolic effects (2000) (4)
Phase II evaluation of triazinate in patients with metastatic lung cancer. (1980) (4)
Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors. (2011) (4)
Molecular genetics of neuroendocrine tumors (1993) (4)
Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. (1979) (4)
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma. (1983) (4)
Tu1564 Predictors of Lymph Node Metastases and Impact on Survival in Resected Pancreatic Neuroendocrine Tumors, a Single Center Experience (2013) (4)
Lymphocele after retroperitoneal node dissection for testis tumor (1986) (3)
Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr(3)-octreotide (SMT487). (2000) (3)
Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma. (1979) (3)
Chemotherapeutic sensitivity of minimal residual disease following surgical excision of ovarian carcinoma. (1978) (3)
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. (2011) (3)
Carcinoids of the Appendix (2004) (3)
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 11-13, 2015, Barcelona, Spain: Abstracts (2015) (3)
Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma (1989) (3)
Somatostatin Receptors in Gastroenteropancreatic Tumors (1996) (2)
Occult primary cancer clinical practice guidelines. (2005) (2)
Clinicopathologic analysis of well, moderately and poorly differentiated gastroenteropancreatic neuroendocrine tumors (2007) (2)
213Bi[Dota0, Tyr3]octreotide (Bi-DOTATOC) in peptide receptor radionuclide therapy (PRRT): Radiolabelling, stability and biodistribution (1999) (2)
Octreotide LAR in carcinoid: how to dose? (2008) (2)
A comparison of intra-arterial and cuff blood pressure measurements in very obese subjects. (1969) (2)
Phase II study of maytansine in advanced breast cancer. (1981) (2)
Incidental diagnosis of pancreatic neuroendocrine tumors. (2011) (2)
Novel progression-associated genes in pancreatic endocrine neoplasms (2008) (2)
Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma. (1980) (2)
Parathyroid carcinomas, pheochromocytomas, and multiple endocrine neoplasia syndromes (2003) (2)
Men 2A, 2B, and Non-Men Familial Medullary Thyroid Carcinoma (2003) (2)
Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. (1988) (2)
Multimodality management of borderline resectable pancreatic neuroendocrine tumors: Sentinel report of a single-institutional experience. (2015) (2)
Cancer: Principles & Practice of Oncology (1986) (2)
Endocrine Neoplasms of the Gastroenteropancreatic (GEP) System (2003) (2)
Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma. (1983) (1)
Is there a role for octreotide in the treatment of hormone-refractory prostate cancer? (2002) (1)
VP-16 in advanced squamous cell and adenocarcinoma of the lung (1978) (1)
Phase II trial of diaziquone in advanced upper aerodigestive cancer. (1985) (1)
Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA,Tyr3]octreotide: Toxicity and efficacy of 4-cycle and single-cycle regimens. (2004) (1)
Octreotide use in patients with metastatic pancreatic neuroendocrine tumors. (2011) (1)
Bisantrene phlebitis may be related to intravascular deposition of drug (1982) (1)
Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
Diagnosis in oncology (1998) (1)
RUNXT1 and Palladin Outperform Pathologic Criteria of Malignancy in Predicting Liver Metastases in Primary Pancreatic Endocrine Carcinomas (2010) (1)
Palladin is a Reliable Marker of Liver Metastasis in Primary Pancreatic Endocrine Neoplasms (2010) (1)
Preface (1994) (0)
Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure. (1983) (0)
Adoption of neuroendocrine tumor (NET) research into treatment guidelines: Are rare cancers neglected? (2010) (0)
Contents Vol. 85, 2007 (2007) (0)
ENETS News Letter (2015) (0)
Clinical and Echocardiographic Spectrum in 74 Patients: Carcinoid Heart Disease (1993) (0)
NEUROENDOCRINE TUMORS (2007) (0)
Carcinoid syndrome. (1998) (0)
Platinum base polychemotherapy versus dianhydrogalactitol (DAG) in advanced non small cell lung cancer (NSCLC) (1977) (0)
Metastasis-Associated Gene Products and Liver Metastases in Pancreatic Endocrine Tumors (2010) (0)
Recent Advances in the Pathogenesis of Pancreatic Endocrine Neoplasms (2010) (0)
Risk of metastatic spread in patients with early-stage, surgically resected pancreatic neuroendocrine tumors. (2011) (0)
213BI-[DOTA0,TYR3]OCTREOTIDE (Bi-DOTATOC) IN PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT): RADIOLABELING, STABILITY, AND BIODISTRIBUTION. (1999) (0)
Contents Vol. 97 (2013) (0)
Front & Back Matter (2012) (0)
ENDSTAGE LIVER DISEASE (ESLD) PATIENTS HAVE ELEVATED NEUROPEPTIDE (NP) LEVELS WHICH FALL AFTER SUCCESSFUL LIVER TRANSPLANTATION (LT) (1993) (0)
Survival in patients with neuroendocrine tumors after treatment with [Y-90-DOTA,Tyr(3)]octreotide in a phase-1 study. (2003) (0)
Molecular Pathology and Diagnostics of Pancreatic Endocrine Neoplasms (2014) (0)
Dr O'Connor and colleagues respond (1994) (0)
Role of immunohistochemistry in the diagnosis of poorly differentiated neuroendocrine carcinoma. (2010) (0)
Potential use of OctreoScan-111 to predict kidney exposure during 90Y-SMT487 therapy (2000) (0)
Pharmacokinetic study of ADAH in humans and sensitivity of ADAH to light (1982) (0)
Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer. (1981) (0)
Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. (2004) (0)
Subject Index Vol. 85, 2007 (2007) (0)
Subject Index, Vol. 54, Supplement 1, 1993 (1993) (0)
Prognostic relevance of a novel AJCC staging classification for neuroendocrine tumors of the pancreas. (2011) (0)
patients with advanced neuroendocrine tumors refractory or resistant to (2012) (0)
Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease. Conference proceedings. Berlin, Germany, November 3-7, 1993. (1994) (0)
Peptide Receptor Analysis in Neuroendocrine Gastroenteropancreatic Tumors (1994) (0)
Occult primary: Clinical practice guidelines in oncology (2008) (0)
The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors (1994) (0)
Subject Index Vol. 11, 1994 (1994) (0)
Sa1568 Diagnostic Performance of EUS-FNA for Cystic and Non Cystic Pancreatic Neuro-Endocrine Tumors: Single Center Experience From the Moffitt Cancer Center (2012) (0)
Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. (2016) (0)
Somatostatin receptors in apudomas: A physiological basis for therapy and a diagnostical tumour marker (1989) (0)
Phase II study of 9–10 anthracene‐dicarboxaldehyde bis(4,5‐dihydro-1 H‐imidazol-2‐yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma (1983) (0)
Books Received in November-December 1980 / Book Reviews (1981) (0)
Discovery and Validation of a Novel Set of Putative Progression Markers in Well-Differentiated Primary Pancreatic Endocrine Carcinomas (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence K. Kvols?

Lawrence K. Kvols is affiliated with the following schools:

Lawrence K. Kvols's Academic­Influence.com Rankings

Why Is Lawrence K. Kvols Influential?

Lawrence K. Kvols's Published Works

Published Works

What Schools Are Affiliated With Lawrence K. Kvols?

Lawrence K. Kvols's AcademicInfluence.com Rankings